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Abstract
Epigenetic mechanisms including DNA methylation are supposed to play a key role in fetal development. Here we have
investigated fetal DNA-methylation levels of 27,578 CpG loci in 47 chorionic villi (CVS) and 16 amniotic cell (AC) samples.
Methylation levels differed significantly between karyotypically normal AC and CVS for 2,014 genes. AC showed more
extreme DNA-methylation levels of these genes than CVS and the differentially methylated genes are significantly enriched
for processes characteristic for the different cell types sampled. Furthermore, we identified 404 genes differentially
methylated in CVS with trisomy 21. These genes were significantly enriched for high CG dinucleotid (CpG) content and
developmental processes associated with Down syndrome. Our study points to major tissue-specific differences of fetal
DNA-methylation and gives rise to the hypothesis that part of the Down syndrome phenotype is epigenetically
programmed in the first trimester of pregnancy.
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Introduction
The epigenetic composition of the fetus has gained much
attention in the recent past. In particular, the patterns of DNA
methylation and their changes during normal and pathologic fetal
development are subject of studies in various fields of research.
These include reproduction failure, effects of assisted reproduc-
tion, disturbances of the maternal-fetal interface, disorders of
development, syndromes caused by errors in imprinting, fetal
programming of behavior or disease or the impact of maternal
factors on fetal development [1–4].
Compared to its sequence the methylation of DNA shows
a much higher plasticity both intra- and interindividually. DNA
methylation patterns differ between tissues and epigenetic
modifications are supposed to be major determinants of the cell
type-specific gene expression program and, thus, to imprint the
cellular protein expression, function and destiny [5,6]. Conse-
quently, DNA methylation patterns can be influenced by internal
and external factors allowing cellular differentiation and response
to exogenic stimuli. The latter is directly linked to the in-
terindividual differences in DNA methylation which have been
shown to increase with ageing by twin studies [7–9]. Considering
this epigenetic plasticity it is intriguing to speculate that differences
in DNA methylation patterns could explain (part of the)
phenotypic differences observed between individuals carrying the
same genetic change. E.g., despite carrying a third chromosome
21 only 40–60% of individuals with Down syndrome are affected
by congenital heart defects, mostly an atrial (ventricular) septal
defect [10–12].
This figure - besides through the effect of modifier genes - could
well be explained by a secondary epigenetic mark influencing
cardiac development established or erased directly or indirectly
through the effect of a gene on chromosome 21.
DNA methylation patterns can also be of relevance for
diagnostics. In this regard, a series of locus-specific and genome-
wide DNA methylation profiling studies has been performed in the
recent past in order to detect methylation patterns differentiating
fetuses with chromosomal aberrations from those with normal
karyotypes. This led to the development of novel approaches for
noninvasive prenatal diagnosis of e.g. trisomy 21 by analysis of
fetal-specific DNA methylation in maternal blood [13].
It is remarkable, that description of fetal trisomic and non-
trisomic fetal DNA methylation patterns, respectively, has so far
been almost exclusively based on the analysis of a limited number
of placental DNA both from first and third trimester pregnancies
[14–18]. Nevertheless, it is well known from prenatal chromo-
somal testing that placental tissue e.g. derived from chorionic villi
sampling (CVS) is a peculiar fetal tissue to study because of the
mixture of ectodermal and mesodermal cells, recurrent mosaicism
and the contamination of fetal tissue by maternal cells. In contrast
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fetus, cells obtained by amniocentesis (AC) which are epithelial
cells derived from the epiblast of the inner cell mass are supposed
to reflect closely the true composition of the fetus [19].
In order to characterize and compare DNA methylation
patterns between amniotic and chorionic tissue samples we
performed an array-based methylation profiling study in an
extensive series of 63 fetal tissues derived from routine prenatal AC
and CVS sampling. Through analysis of CVS samples from fetuses
with trisomy 21 we unravel potential novel markers for non-
invasive prenatal testing. Finally, by describing the molecular
features shared by the genes differentially methylated between the
different tissues as well as the CVS samples with and without
trisomy 21 we provide initial insights into the biological processes
underlying epigenetic patterns in normal fetal differentiation and
development as well as potentially in the manifestation of the
typical phenotype of Down syndrome.
Materials and Methods
Study Population
The study was performed on 63 samples from 61 different
women left over from routine prenatal cytogenetic testing. This
included 47 chorionic villi samples (CVS) and 16 samples derived
from amniocentesis (AC). CVS and AC sampling was performed
with written informed consent of the patients according to
standard methods. The main indications for invasive prenatal
testing were advanced maternal age as well as abnormal
ultrasound findings such as elevated nuchal translucency (NT) or
abnormal first trimester screening. Clinical details on the
pregnancies as well as pregnancy outcome are summarized in
Table S1. For control purposes peripheral blood samples from
normal female and male individuals were included. The study was
approved by the Ethics Committee of the Medical Faculty of the
Christian-Albrechts-University Kiel (IRB No: D447/09, D402/
09).
DNA Extraction
DNA was extracted from native CVS tissue left over after
setting up direct preparations and long-term cultures for cytoge-
netic analyses as well as from long-term cultured AC cells. Samples
were cryopreserved until DNA extraction. DNA extraction was
performed centrally by a single person to widely exclude batch
effects applying the High Pure PCR Template Preparation Kit
(Roche Diagnostics, Mannheim, Germany).
DNA Methylation Analysis
DNA methylation analysis using the HumanMethylation27k
BeadChip (Illumina Inc., San Diego, CA, USA) was performed
using a custom service provided by AROS Applied Biotechnology
AS (Aarhus, DK). The HumanMethylation27 BeadChip was
developed to assay 27,578 CpG sites selected from more than
14,000 genes in parallel [20]. Two samples were analyzed in
duplicates using different batches of the HumanMethylation27
BeadChip. Array data are available in a MIAMI compliant format
from GeneOmnibus (GSE35327).
Processing of Data and Bioinformatic Analyses
Raw hybridisation signals were processed using GenomeStudio
software (ver. 2011.1; Illumina Inc.) applying the default settings.
Further analyses were performed using the R-package [21] and
RStudio (ver. 0.94.102) using raw data obtained from the
GenomeStudio analysis. Color balance adjustment and data
normalization (simple scaling normalization) were done using the lumi
package for R [22–24]. CpG loci with detection p-values,0.001
in at least one of the samples analyzed were excluded from further
analyses. Finally, 22234 CpG loci in 63 samples entered analysis.
Data obtained from samples analyzed in duplicates were averaged.
Subsequent principal component (PCA) and hierarchical cluster
analyses were performed using Qlucore’s Omics Explorer 2.1
(Version 2.1(25); Qlucore, Lund, Sweden). Genes were considered
being differentially methylated between two data sets if the false
discovery rate (FDR) was below q,0.01 (t-test). The R-package
was used to perform Pearson’s product-moment correlation.
Bioinformatic Characterisation of Groups of Differentially
Methylated Genes
To analyze whether promoter regions of differentially methyl-
ated genes showed different CpG compositions, we used a pre-
viously described classification into promoters with high (HCP),
intermediate (ICP) and low (LCP) CpG content [25,26]. Propor-
tions of PRC2 target genes and promoter classes in the groups of
genes differentially methylated and all genes present on the
HumanMethylation27 Bead Chip were compared using the chi-
square test (two-sided; GraphPad Prism, ver. 4.02). A genome-
wide mapping of PRC2 genes in embryonic stem cells is available
as supplemental material in the study by Lee et al. [27]. Imprinted
genes were identified from publicly available databases (http://igc.
otago.ac.nz/home.html26 and http://www.geneimprint.com/
site/genes-by-species27) and a previously published review [28].
Gene ontology analysis has been performed using GOrilla [29]
with a list of genes present on the BeadChip acting as background
list.
Bisulfite Pyrosequencing of KIAA0575, ECEL1, SOX11 and
STG4
Bisulfite conversion of genomic DNA was performed using the
EpiTect Bisulfite Conversion Kit (Qiagen, Hilden, Germany)
according to the manufacture’s protocol. Bisulfite Pyrosequencing
was performed according to previously published protocols [30].
Primer sequences and precise PCR conditions are available from
the authors on request. DNA-methylation of KIAA0575, ECEL1,
SOX11 and STG4 has been analyzed in this study.
GeneScan analysis of the AMELX/AMELY locus. To
determine the content of fetal tissue in CVS samples obtained
from male fetuses we performed a PCR based GeneScan analysis
on the AMEL gene locus using primers yielding different sized
PCR fragments from the X-chromosomal (AMELX, Xp22.2) and
Y-chromosomal (AMELY, Yp11.2) copy of the gene. PCR
fragments were analyzed using an ABI 3100 (Applied Biosystems,
Carlsbad, CA). DNAs from peripheral blood of normal males
(n=6), normal females (n=5) as well as mixtures of normal male
and female DNA (ratio: 1:1, n=5) acted as control. The ratios of
the peak area of X- and Y-chromosomal specific peaks were
calculated. Using the controls as standard values in a regression
analysis, the content of fetal tissue in CVS samples has been
determined in CVS samples from male fetuses.
Results
Applying the ‘‘Infinium HumanMethylation27 BeadChip’’ we
investigated 27,578 CpG sites selected from more than 14,000
genes in a series of 63 fetal tissues left over from routine prenatal
genetic testing. In particular, we investigated 47 chorionic villi
samples (CVS) and 16 samples derived from amniocentesis (AC).
Besides samples from fetuses with normal male or female
karyotype these included six cases with trisomy 18 (5 CVS, 1
AC) and three cases with trisomy 21 (all CVS). One CVS sample
DNA-Methylation Profiling of Fetal Tissues
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39014was derived from a fetus with a gonosomal chromosome pattern
typical for Turner Syndrome. Two samples (1 AC, 1 CVS with
trisomy 21) were obtained from pregnancies induced by
intracytoplasmatic sperm injection (ICSI). None of the chromo-
somal aberrations was mosaic. Clinical details are summarized in
Table S1.
The reproducibility and validity of the applied array platform
for determination of DNA-methylation levels has been extensively
demonstrated by us in previous studies using different types of
samples and comparison to alternative techniques like methylation
specific PCR, bisulfite pyrosequencing or bisulfite sequencing [31–
33]. In addition, we here investigated the reproducibility by
analyzing two pairs of CVS samples in duplicate (CV21 and 19;
CV26 and 10; Table S1) using two different batches of the array.
This comparison yielded Pearson correlation coefficients of 0.96
and 0.97, respectively, indicating good reproducibility also in the
fetal samples under study (Figure S1). Moreover, to test the validity
of the DNA methylation values derived from the array we here
examined the status of 6 CpG loci in 3 randomly selected AC und
7 CVS samples by bisulfite pyrosequencing (Figure S2).
Having established the technical validity of the array we aimed
in a first step at comparing the DNA-methylation between the
amniotic cells and the chorionic samples with a regular karyotype.
To this end, we excluded all samples with a chromosomal
aberration. Moreover, we excluded the samples of pregnancies
derived after ICSI in order to avoid putative effects of in vitro
fertilization on the epigenetic pattern. Already an unsupervised
principal component analysis (PCA) of the complete data set from
the remaining 50 samples clearly separated AC from CVS samples
(Figure 1a). This indicates that the methylation patterns of the
samples investigated are much stronger associated with the origin
of the fetal tissue than other factors like sex of the fetus despite the
X-chromosome undergoing DNA-methylation in females is being
included in the analysis. A supervised comparison identified 2418
CpG loci corresponding to 2014 individual genes to be signifi-
cantly (FDR,1610
215, t-test) differentially methylated between
AC and CVS (Figures 1b and 1c). Like in the unsupervised
analysis the samples clustered independently from the sex of the
fetus (Figure 1c). We conclude that there are major differences in
the DNA-methylation patterns between the fetal tissues obtained
by routine invasive prenatal testing.
Interestingly, inspection of the heatmap (Figure 1c) suggested
that the methylation values of the genes differentially methylated
between amniotic and chorionic samples are more extreme in AC
than those in CVS. To further investigate this observation, we
plotted the means of the normalized methylation values in AC and
CVS of all differentially methylated 2418 CpG loci. As shown in
Figure 2, these loci were preferentially (2054 of 2418 CpG loci)
intermediately methylated in CVS but either lowly or highly
DNA-methylated in AC samples. In contrast, genes not differen-
tially methylated between CVS and AC showed a similar DNA
methylation distribution pattern in both sample types (Figure S3).
We conclude that the genes differentially methylated between AC
and CVS are predominately characterized by more extreme
DNA-methylation levels in the former and more intermediate
levels in the latter samples.
The more intermediate methylation levels of the genes
differentially methylated between amniotic and chorionic samples
could be due to the fact that tissue sampled by CVS is a mixture of
various embryonic and also maternal cell compartments. In
contrast, cells derived from AC usually lack maternal contamina-
tion if the sample is not contaminated by blood. The potential
differences in the contribution of maternal cells between AC and
CVS prompted us to investigate the correlation of the DNA-
methylation patterns with fetal sex. Unsupervised analysis of the
50 samples already suggested that fetal sex was less visible in the
methylation pattern of CVS than in AC. To corroborate this
observation we focused on the X-chromosomal genes as many (but
not all) of those are being methylated in 50% of the X-
chromosomes of females due to X-inactivation not present in
normal males. In an unsupervised approach both AC and CVS
samples separated according to fetal sex based on the methylation
levels of the X-chromosomal genes. Nevertheless, three CVS
samples from male fetuses clustered separately from the other CVS
samples of male fetuses (Figure 3, arrow). These three samples
showed a mixture of male and female X-chromosomal methyla-
tion patterns likely due to maternal cells contaminating the CVS
sample. We conclude that varying maternal contribution affects
the DNA methylation pattern of CVS samples. This is further
supported by a GeneScan analysis of the AMELX/AMELY locus in
CVS samples derived from male fetuses revealing a detectable
maternal contamination of between 0% and 29% (median 17%).
Next we wondered whether the 2014 genes differentially
methylated between amniotic and chorionic samples share certain
biological features. Several studies demonstrated that genes with
promoters either containing a high CpG content (HCP) or a low
CpG content (LCP) show different DNA methylation properties
[31–33]. The 628 genes found hypermethylated in CVS compared
to AC were significantly enriched for polycomb repressor complex
2 (PRC2) target genes in embryonic stem cells (p,0.0001;
OR=3.88, RR=3.51) and imprinted genes (p,0.0001,
OR=2.69, RR=2.50), while LCP genes were depleted
(p=0.0213, OR=0.77, RR=0.78). In contrast, the 1406 genes
hypermethylated in AC in comparison to CVS were significantly
enriched for genes with LCPs (p,0.0001, OR=4.39, RR=3.62)
but depleted for HCP genes (p,0.0001, RR=0.29, OR=0.26)
and PRC2 target genes in embryonic stem cells (p,0.0001,
RR=0.35, OR=0.33).
We further investigated whether genes differentially methylated
between AC and CVS were enriched for certain biological
functions by performing a gene ontology analysis. This approach
revealed that the 2014 genes differentially methylated between AC
and CVS were significantly enriched for genes involved in various
regulatory and developmental processes including e.g. regulation
of adenylate cyclase activity which might point e.g. to hormonal or
neuronal signaling (Table S2). In addition, the physiologic
properties of the cell compartments analyzed are reflected by
significant enrichment of the differentially methylated genes for
processes ‘‘(cellular) response to nitric oxide’’ (5.3–6.3fold;
containing predominately genes encoding surfactant proteins),
‘‘keratinization’’ (2.8fold) or ‘‘female pregnancy’’ (2.4fold). A
detailed list of loci aberrantly methylated in CVS samples with
trisomy 21 and trisomy 18 along with the corresponding DNA
methylation values of the respective loci in normal peripheral
blood is available from the supplement (Table S4). Applying
a threshold of delta.beta.0.2 we identified 89 loci with differential
methylation between CVS with trisomy 21 and both normal CVS
as well as peripheral blood samples from normal females. All of
these loci were hypermethylated in trisomy 21 samples.
One single locus (CACNA1H, cg25760229) was differentially
methylated between CVS with trisomy 18 and both normal CVS
and peripheral blood samples from normal females (hypermethy-
lated in trisomy 18 samples).
Finally, we wondered whether maternal factors could be
associated with methylation differences in CVS and AC samples
with normal karyotype. Due to the tissue differences shown above
we treated both sample sources differently. By PCA we failed to
detect any significant effect of maternal age, BMI or smoking
DNA-Methylation Profiling of Fetal Tissues
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39014Figure 1. DNA methylation differs between AC and CVS samples. (A) Principal component analysis (PCA) of 22,234 CpG loci which passed
quality tests and entered the analysis. Unsupervised analysis separated AC (green spheres) from CVS samples (red spheres). (B) Differential
methylation analysis to separate AC from CVS samples (t-test, FDR,1610
215). (C) Hierarchic cluster analysis of the 2418 CpG loci shown in (B). The
upper panel on top of the heatmap indicates the sample type (green: AC, red:CVS) while the second panel indicates the fetuses’ sex (pink: female,
cyan: male). Green color in the heatmap indicates low DNA-methylation, black intermediate and red high DNA-methylation values. Samples with
known chromosomal aberrations and samples from ICSI were excluded. AC and CVS differ significantly in their DNA methylation pattern.
doi:10.1371/journal.pone.0039014.g001
Figure 2. CpG loci differentially methylated between AC and CVS samples preferentially show an intermediate methylation level in
CVS. Scatter plot of the means of DNA methylation values of all 2418 CpG loci differentially methylated between samples obtained by amniocentesis
(AC, green circle) and chorionic villi biopsy (CVS, red circle) samples (FDR,1610
215). For all loci the means have been calculated in AC and CVS
separately and subsequently plotted. Most CpG loci are characterized by either a high or a low DNA methylation value in AC but an intermediate DNA
methylation value in CVS.
doi:10.1371/journal.pone.0039014.g002
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(data not shown). Probably, the number of samples under
investigation was too low to get a conclusive significant result.
Having determined the methylation patterns in AC and CVS
samples with normal karyotypes we aimed in the second part of
the analyses at investigating whether fetal trisomies were
associated with an altered DNA-methylation pattern. We limited
the bioinformatic analyses to the CVS samples as the number of
fetuses with a trisomy in the AC population was too low. In the
three CVS samples with a fetal trisomy 21 (including one
conceived by ICSI) a total of 464 loci (Figure 4; q,0.01)
corresponding to 404 genes were differentially methylated as
compared to CVS samples with a normal karyotype. Remarkably,
the vast majority (387/404) of the genes was hypermethylated in
the trisomic samples and only 17 hypomethylated. The 387
hypermethylated genes in trisomy 21 were significantly enriched
for genes with HCP content (p=0.0244, OR=1.27, RR=1.28),
known PRC2 target genes in embryonic stem cells (p,0.0001,
OR=4.37, RR=4.07) and (known or suggested) imprinted genes
(p,0.0001, OR=3.23, RR=3.03), while genes with LCP were
significantly depleted (p=0.0002, OR=0.55, RR=0.56). In
contrast the 17 hypomethylated genes were significantly enriched
only for genes with HCP content (p=0.0146, OR=5.93,
RR=5.92). Gene ontology analysis of all 404 aberrantly
methylated genes in cases with trisomy 21 showed a significant
enrichment of several processes in development, embryogenesis
and signaling which could be associated with the typical
phenotype of Down syndrome, including ‘‘neuron fate determi-
nation’’ (15.2fold), ‘‘meso/metanephros development’’ (9.4fold,
5.9fold), ‘‘heart morphogenesis’’ (5.5fold), ‘‘eating/feeding behav-
ior’’ (11.9fold, 6.2fold) or ‘‘embryonic digestive tract morphogen-
esis’’ (9.5fold) (Table S3).
In contrast to the samples with trisomy 21, an analysis
comparing the five CVS samples with trisomy 18 to the normal
controls identified only 15 significantly differentially methylated
loci, corresponding to 14 genes (Figures 4c and 4d). No significant
enrichment of any properties of the genes was detected.
Finally, we wondered whether the single sample of AC with
trisomy 18, the CVS sample with a gonosomal chromosome
pattern typical for Turner Syndrome and the AC samples derived
from a pregnancy after ICSI showed peculiar patterns of
methylation. Obviously, bioinformatic analysis of single samples
is meaningless. Nevertheless, displaying the methylation pattern of
the X-chromosomal genes in the Turner sample as compared to
the mean values of the normal male and female CVS samples
showed lack of both, the typical female X-inactivation pattern and
of the male methylation pattern (Figure S4). Finally, displaying the
two ICSI samples as compared to the normal AC and CVS
samples with regard to the genes differentially methylated between
both tissues showed a remarkable loss of methylation in the ICSI
derived AC sample (Figure S5). This might point to changes in the
DNA methylation detectable in AC samples derived from ICSI
patients but warrants further investigation.
Discussion
In the present study we performed array-based methylation
profiling on an extensive series of fetal samples with normal and
aberrant karyotypes obtained by routine prenatal CVS and AC
sampling. Obviously, relying on left-over samples from routine
prenatal testing implements a certain selection bias as with few
exceptions only fetuses at risk for chromosomal aberrations and/or
with abnormal ultrasound findings or maternal serum screenings
will be sampled due to ethical considerations. Thus, the present
series was enriched for pregnancies with normal karyotype but
abnormal ultrasound (n=12), aberrant first trimester screen
(n=23) or advanced maternal age (n=41) (multiple answers were
permitted). Moreover, samples with known chromosomal aberra-
tions were included on purpose. Thus, the analyses provided here
reflect the findings of an ‘‘at-risk’’ cohort rather than of the normal
distribution of pregnancies.
Moreover, it needs to be taken into account that whereas native
(cryopreserved) CVS samples were investigated without prior
culturing the AC cells had to be cultured to obtain sufficient
amounts of DNA for the analyses. In this regard it needs to be
considered that amplification of unmodified DNA prepared from
uncultured AC cells would not have been suitable for the
methylation arrays applied as by the amplification process the
DNA methylation marks get lost. In turn, amplification of bisulfite
treated DNA might have introduced experimental biases due to
selective amplification of methylated or unmethylated DNA. The
minute DNA amounts left over after routine diagnostics from
uncultured amniotic cells might also be the reason why hitherto
genome-wide methylation profiling studies focused on CVS or
placental samples. Obviously, culturing cells harbors the risk of
changing the DNA methylation pattern. Nevertheless, based on
our own and others reports on lymphoblastoid cell lines as
compared to normal lymphocytes we think that the culture-
induced methylation changes are minor as compared to the tissue-
specific differences which were in the focus of the present study
[31]. To further evaluate this assumption we determined the
predicted cumulative population doublings, predicted passages
and the predicted time in culture using the tool available at http://
www.molcell.rwth-aachen.de/dms. Based on the DNA methyla-
tion values of seven CpG loci present on the HumanMethyla-
tion27k Bead Chip Koch et al. developed an algorithm to
investigate these parameters from in vitro cultured cells [34]. As
calculated by this tool, the cumulative population doublings
Figure 3. Hierarchic cluster analysis of DNA methylation values
of 767 X-chromosomal CpG loci present on the array. The upper
panel on top of the heatmap indicates the sample type (green: AC, red:
CVS) while the second panel indicates the fetuses’ sex (pink: female,
cyan: male). Samples with known chromosomal aberrations and
samples from ICSI were excluded. Three CVS samples from male
fetuses show a DNA methylation pattern similar to female samples
(arrow). A blue bar at the right site indicates genes methylated
specifically in male fetuses, an orange bar genes methylated in female
samples and a black bar genes with tissue- specific DNA methylation.
doi:10.1371/journal.pone.0039014.g003
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to 12 (median=2) and the predicted time in culture from 18 to 64
(median=7.5) in AC samples. All these values were lower than
those calculated from uncultured CVS cells supporting our
assumption that the methylome of the in vitro cultured AC
samples might not be heavily altered in culture.
Even taking into account potential sampling and culturing
artifacts the differences in the methylation patterns between CVS
and AC samples with normal karyotype were striking. Investigat-
ing nearly 800 selected genes using the Illumina GoldenGate DNA
Methylation Cancer Panel I array, Yuen et al. [35] recently
identified 195 sites (23%) to be differentially methylated between
various fetal studies. Here 2418 CpG loci corresponding to 2014
individual genes, i.e. almost 11% of all CpGs on the array, showed
a differential methylation between the two tissues studied. This
strong difference is most likely attributed to the fact that CVS
samples derive from chorionic ectoderm (trophoblast) and extra-
embryonic mesoderm and blood whereas cells sampled by AC are
all of embryonic ectodermal origin including epithelial cells from
the embryonic surfaces and from the amnion [19]. Indeed, the
gene ontology analyses support this view showing on the one hand
enrichment of genes involved in more fetal ectodermal or
epithelial functions like keratinization or response to nitric oxide
(mediated by surfactant proteins) and on the other hand more
trophoblastic and extra-embryonic functions including many
pregnancy associated hormones and proteins (see Table S2).
A striking feature of loci differentially methylated between CVS
and AC were the preferentially intermediate methylation levels of
these loci in CVS in contrast to the extreme DNA-methylation
levels in AC samples (Figure 2). DNA methylation in normal
tissues shows for the majority of genes a bimodal distribution, i.e.
full methylation or no methylation [20,31]. This pattern was
indeed observed in both AC and CVS samples. The enrichment of
intermediate methylation levels in the genes differentially meth-
ylated between AC and CVS is inherent to this set of genes. A
technical bias seems unlikely as the validity of the array has been
proven previously and in the present set of samples by independent
techniques. Also a bioinformatic bias seems unlikely due to the fact
that intermediate methylation levels in CVS were present in 85%
of the differentially methylated genes and in AC only in 15% of
those genes. Moreover, the DNA methylation pattern of these
CpG loci in AC was similar to the pattern found in peripheral
blood of adults (data not shown). Finally, the genes hypermethy-
lated in AC were significantly enriched for genes with LCPs (but
depleted for HCP and PRC2 target genes in embryonic stem cells)
suggesting a role in somatic tissue-specificity. Overall, these
observations are in remarkable agreement with a recent report
by Novakovic et al. [36] who showed that there is a progressive
increase in average methylation in human placentas from first to
third trimester. Using also the Infinium HumanMethylation27
BeadChip these authors have demonstrated that this progress
particularly affects genes with an intermediate (beta value .0.6)
methylation level and non-CpG island (i.e. LCP) genes. AC
samples are usually obtained 2–10 weeks later in pregnancy than
CVS samples. Therefore the intermediate methylation levels
characteristic of CVS samples might reflect the different origin of
the cells in such a sample. A different explanation is that in earlier
weeks of pregnancy there is a higher epigenetic instability,
comparable to the increased propensity for chromosomal mosa-
icism in the early placenta. The latter might be supported by the
fact, that placental tissue also genetically is frequently mosaic [37].
Another feature which explains intra-sample heterogeneity
might be contamination with maternal cells. By analysis of X-
chromosomal methylation patterns we show (here) that such
Figure 4. DNA methylation patterns in CVS samples with chromosomal imbalances. PCA (A) and Hierarchic cluster analysis (B) of DNA
methylation values of 464 CpG loci differentially methylated between chorionic villi biopsy samples without chromosomal imbalances (red spheres or
red squares, respectively) and samples with trisomy 21 (47,XY+21; blue spheres or blue squares, respectively) (FDR,0.01). While in cases with trisomy
21 numerous epigenetic alterations could be identified, in cases with trisomy 18 (47,XX+21/47,XY+21, yellow spheres or yellow squares) only 15
differentially methylated loci have been found (C and D). Green color in the heatmap indicates low DNA-methylation, black intermediate and red high
DNA-methylation values.
doi:10.1371/journal.pone.0039014.g004
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the fetal sex via methylation-based X-inactivation patterns. In
contrast to the CVS samples cultured cells derived from AC
usually lack maternal contamination.
We failed to identify any association of maternal factors like
maternal age, BMI or smoking status on the methylation pattern
in AC and CVS likely due to the small size of the cohort for such
analyses. In line with this, targeted analysis of the F2RL3 locus
recently shown to be differentially methylated in peripheral blood
with regard to the smoking status [38] showed no different
methylation levels in samples depending on the maternal smoking
status.
Analyses of the association of karyotypic aberrations with DNA
methylation levels had to be restricted to CVS samples due to the
low number of AC samples with such changes. The intra-sample
variability of CVS samples described above might be the cause
that we only detected 15 loci, corresponding to 14 genes (Figures 4c
and 4d) significantly differentially methylated between CVS
samples with and without trisomy 18. In contrast, we identified
a total of 464 loci (Figure 4; q,0.01) corresponding to 404 genes
which were differentially methylated in samples with trisomy 21 as
compared to CVS samples with a normal karyotype. It needs to be
emphasized that the array applied in this study aims at a genome-
wide coverage whereas several previous studies comparing DNA
methylation between trisomic and normal CVS/placental samples
focused on CpGs on the affected chromosomes, i.e. 18 or 21
[14,23,39]. A recent postnatal study investigated peripheral blood
samples and isolated T-cells of individuals with Down syndrome as
compared to controls on the same array platform like the one
applied by us identified 108 genes (118 probes) and 140 CpGs (134
genes) to be differentially methylated in Down syndrome [40].
Nevertheless differences in the methylation profiles between
individuals with and without trisomy 21 have been shown to be
tissue specific [35].
Remarkably, in trisomy 21 fetuses studied herein more than
95% (387/404) of the differentially methylated genes were
hypermethylated as compared to normal CVS samples. Only 3/
387 hypermethylated (COL6A2, H2BFS, RUNX1) and 1/17
hypomethylated (MCM3AP) genes are located on chromosome
21. Thus, the trisomy 21 is associated with a genome-wide
perturbance of DNA methylation not restricted to chromosome 21
that predominately leads to hypermethylation. This is in line with
the pattern of differentially methylated genes observed by Kerkel
et al. [40] on postnatal blood samples of individuals with trisomy
21. None of the nine genes identified by Kerkel et al. being
aberrantly methylated in peripheral blood samples of patients with
trisomy 21 have been identified by us. However, the focus of the
study by Kerkel et al. and this study differs in the stage of
development and the tissues analyzed. In our study, only 112 of
the 404 genes belong to the 2014 genes showing tissue-specific
differential methylation between CVS and AC suggesting that the
deviation from the physiologic pattern in CVS might also be
representative for other tissues. Remarkably, both differentially
hypo- and hypermethylated genes in trisomy 21 were enriched for
HCP content. Moreover, the 387 hypermethylated genes in
trisomy 21 were significantly enriched for known PRC2 target
genes in embryonic stem cells while genes with LCP were
significantly depleted. This might suggest that many of those genes
differentially methylated in trisomy 21 are indeed relevant for
prenatal development. In line with this, the aberrantly methylated
genes in cases with trisomy 21 show a remarkable enrichment of
genes involved in processes of neuronal, heart, kidney, gut or facial
bone (e.g. palate) development. Considering the phenotype of
Down syndrome which frequently includes developmental dis-
orders of the named organs it is intriguing to speculate that trisomy
21 exerts its pleiotropic effects via deregulation of an epigenetic
modifier. Such a modifier might be localized in the Down
syndrome critical region in chromosome 21 or could be
deregulated indirectly e.g. through a transcript located on
chromosome 21. Indeed, such a hypothesis could explain to
a considerable extend the intra-individual variation in the Down
syndrome phenotype as the levels of DNA methylation and its
distribution in different tissues might vary and thus could explain
differences in expressivity.
In summary, our extensive array-based survey of fetal sample
obtained by routine prenatal invasive testing points to major
tissue-specific differences of fetal DNA-methylation and gives rise
to the hypothesis that part of the Down syndrome phenotype is
epigenetically programmed in the first trimester of pregnancy.
Supporting Information
Figure S1 Reproducibility of the BeadArray based DNA
methylation analyses as measured by Pearson coeffi-
cients. Two CVS samples have been hybridized separately in
independent experiments using different batches of arrays.
(TIF)
Figure S2 Verification of results obtained from Bea-
dArray analysis by bisulfite pyrosequencing (BPS). 6
CpG loci have been analyzed both by BPS (A, upper table, values
represent % methylation) and by BeadChip technology (A, lower
table; average beta values are shown) in the same samples. The
color code indicates methylation value (green: low, black:
intermediate, red: high DNA methylation). (B) Scatter plots of
results obtained in (A). Pearson’s product-moment correlation
r
2=0.69
(TIF)
Figure S3 The majority of CpG loci present on the array
are comparably methylated in CVS and AC samples.
Histograms showing the frequency of the DNA methylation values
in CVS (A) and AC (B). Scatter plot comparing DNA methylation
values of CVS and AC samples (C). Histograms and scatter plots
show DNA methylation values of CpG loci not differentially
methylated between AC and CVS (FDR.1610
215, t-test).
Pearson’s product-moment correlation r
2=0.94.
(TIF)
Figure S4 Hierarchic cluster analysis of DNA methyla-
tion values of 767 X-chromosomal CpG loci present on
the array. The upper panel on top of the heatmap indicates the
sample type (green: AC, red: CVS) while the second panel
indicates the fetuses’ sex (pink: female, cyan: male). The third
panel indicates normal karyotype (yellow) versus Turner syndrome
(black). Three CVS samples from male fetuses show a DNA
methylation pattern similar to female samples (arrow). A blue bar
at the right site indicates genes methylated specifically in male
fetuses, an orange bar genes methylated in female samples and
a black bar genes with tissue- specific DNA methylation.
(TIF)
Figure S5 The AC sample derived from a pregnancy
after ICSI showed a peculiar pattern of methylation.
PCA (A) and hierarchic cluster analysis of DNA methylation
values of 2418 CpG loci differentially methylated between AC
(green sphere (A) or green square (B)) and CVS (red sphere (A) or
red square (B)) (t-test, FDR,1610
215). One AC sample from
ICSI is indicated by a blue sphere (A) or a blue square (B),
respectively.
(TIF)
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cluded in the study.
(XLS)
Table S2 Gene ontology terms (GO) significantly en-
riched in the group of genes differentially methylated
between CVS and AC samples as compared to the
entirety of loci present on the array (p,0.001, GOrilla
tool: GOprocess).
(XLS)
Table S3 Gene ontology terms (GO) significantly en-
riched in the group of genes differentially methylated
between CVS samples without chromosomal imbalances
and samples with known trisomy 21 as compared to the
entirety of loci present on the array (p,0.001, GOrilla
tool: GOprocess).
(XLS)
Table S4 DNA methylation values (avg.beta and nor-
malized data) of loci differentially aberrantly methylat-
ed in trisomy 21 (sheet 1) and trisomy 18 (sheet 2). Data
from CVS (trisomy and CVS) as well as from peripheral blood
samples from normal female and male donors are included.
(XLS)
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